- Home
- EML vs TLSI Comparison
EML vs TLSI Comparison
Compare EML & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- TLSI
- Stock Information
- Founded
- EML 1858
- TLSI 2010
- Country
- EML United States
- TLSI United States
- Employees
- EML N/A
- TLSI N/A
- Industry
- EML Industrial Machinery/Components
- TLSI Medical Specialities
- Sector
- EML Consumer Discretionary
- TLSI Health Care
- Exchange
- EML Nasdaq
- TLSI Nasdaq
- Market Cap
- EML 141.7M
- TLSI 204.0M
- IPO Year
- EML N/A
- TLSI N/A
- Fundamental
- Price
- EML $24.00
- TLSI $5.04
- Analyst Decision
- EML
- TLSI Strong Buy
- Analyst Count
- EML 0
- TLSI 5
- Target Price
- EML N/A
- TLSI $10.90
- AVG Volume (30 Days)
- EML 12.2K
- TLSI 155.6K
- Earning Date
- EML 08-05-2025
- TLSI 08-13-2025
- Dividend Yield
- EML 1.83%
- TLSI N/A
- EPS Growth
- EML N/A
- TLSI N/A
- EPS
- EML N/A
- TLSI N/A
- Revenue
- EML $271,440,503.00
- TLSI $32,141,000.00
- Revenue This Year
- EML $1.56
- TLSI $55.52
- Revenue Next Year
- EML $7.00
- TLSI $54.76
- P/E Ratio
- EML $11.25
- TLSI N/A
- Revenue Growth
- EML 8.15
- TLSI 46.20
- 52 Week Low
- EML $19.06
- TLSI $3.50
- 52 Week High
- EML $35.03
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- EML 58.59
- TLSI 45.84
- Support Level
- EML $21.78
- TLSI $4.78
- Resistance Level
- EML $23.83
- TLSI $5.20
- Average True Range (ATR)
- EML 0.57
- TLSI 0.31
- MACD
- EML 0.06
- TLSI -0.03
- Stochastic Oscillator
- EML 100.00
- TLSI 30.29
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.